Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Terminated 5Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 16Radiosurgery 12Bevacizumab 12Radiotherapy 10Radiation 8pembrolizumab 6Specimen Handling 6Methotrexate 6Surgical Procedures, Operative 5Topotecan 4TIC10 compound 4Isotretinoin 4Carmustine 4Carboplatin 4abemaciclib 3Trastuzumab 3Thiotepa 3Standard of Care 3Nivolumab 3Magnetic Resonance Imaging 3Lomustine 3Irinotecan 3Erlotinib Hydrochloride 3Drug Therapy 3Dexamethasone 3vandetanib 2thymoglobulin 2temsirolimus 2pazopanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × O(6)-benzylguanine × CNS × Clear all
NCT00046878 2013-03-28

Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Duke University

Phase 2 Withdrawn
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡